Tipifarnib in the treatment of acute myeloid leukemia

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 415-424

  Thomas, Xavier ^a   Elhamri, Mohamed ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; Farnesyltransferase inhibitor; Prognosis; Targeted therapy; Tipifarnib

Indexed keywords

EID: 83255168358     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Alvarez RH, Kantarjian H, Garcia-Manero G, et al. 2006. Farnesyl transferase inhibitor (tipifarnib, Zarnestra; Z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabine (ara-C) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Blood, 108:565a-566a.
2. Appelbaum FR, Gundacker H, Head DR, et al. 2006. Age and acute myeloid leukemia. Blood, 107:3481-5.
3. Ashar HR, James L, Gray K, et al. 2000. Transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem, 275:30451-7.
4. Aspuria PJ, Tamanoi F. 2004. The Rheb family of GTP-binding proteins. Cell signal, 16:1105-12.
5. Basso AD, Mirza A, Liu G, et al. 2005. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem, 280:31101-8.
6. Basso AD, Kirschmeier P, Bishop WR. 2006. Farnesyl transferase inhibitors. J Lipid Res, 47:15-31.
7. Boguski MS, McCormick F. 1993. Proteins regulating Ras and its relatives. Nature, 366:643-54.
8. Bonni A, Brunet A, West AE, et al. 1999. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -inde-pendent mechanisms. Science, 286:1358-62.
9. Bos JL. 1989. Ras oncogenes in human cancer: a review. Cancer Res, 49:4682-9.
10. Brunner TB, Hahn SM, Gupta AK, et al. 2003. Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations. Cancer Res, 63:5656-68.
11. Burgering BM, Coffer PJ. 1995. Protein kinase B (c-Akt) in phosphatidylinositol-3-kinase signal transduction. Nature, 376:599-602.
12. Caplan AJ, Cyr DM, Douglas MG. 1992. YDJ1p facilitates polypeptide translocation across different intracellular membranes by a conversed mechanism. Cell, 71:1143-55.
13. Cates CA, Michael RL, Stayrook KR, et al. 1996. Prenylation of oncogenic human PTP (CAAX) protein tyrosine phosphatases. Cancer Lett, 110:49-55.
14. Cox AD, Toussaint LG III, Fiordalisi JJ, et al. 2001. Farnesyltransferase and geranylgeranyltransferase inhibitors The saga continues. In: SM Sebti and AD Hamilton eds. Farnesyltransferase inhibitors in cancer therapy. Totowa, NJ: Humana Press Inc. p 255-73.
15. Cox AD, Der CJ. 2002. Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol, 2:388-93.
16. Crul M, de Klerk GJ, Swart M, et al. 2002. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol, 20:2726-35.
17. Davies RJ. 1995. Transcriptional regulation by MAP kinases. Mol Reprod Dev, 42:459-67.
18. Du W, Prendergast GC. 1999. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res, 59:5492-6.
19. Elam C, Hesson L, Vos MD, et al. 2005. RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential. Cancer Res, 65:3117-25.
20. Ellis S, Mellor H. 2000. Regulation of endocytic traffic by Rho family GTPases. Trends Cell Biol, 10:85-8.
21. End DW. 1999. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs, 17:241-58
22. End DW, Smets G, Todd AV, et al. 2001. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res, 61:131-7.
23. Estey EH, Thall PF, Wang XM, et al. 2006. Comparison of survival times after administration of tipifarnib or Ara-C-containing therapy, to older patients with newly-diagnosed acute myeloid leukemia. Blood, 108:217b.
24. Fenaux P, Raza A, Mufti GJ, et al. 2007. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediateto high-risk myelodysplastic syndrome. Blood, 109:4158-63.
25. Gau CL, Kato-Stankiewicz J, Jiang C, et al. 2005. Farnesyl-transferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol Cancer Ther, 4:918-26.
26. Harousseau JL, Lancet JE, Reiffers J, et al. 2007. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood, 109:5151-6.
27. Kamasani U, Huang M, Duhadaway JB, et al. 2004. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res, 64:8389-96.
28. Kantarjian H, O'Brien S, Cortes J, et al. 2006. Results of intensive chemotherapy in 998 patients aged 65 and older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer, 106:1090-8.
29. Karp JE, Lancet JE, Kaufmann SH, et al. 2001. Clinical and biological activity of the farnesyltranferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood, 97:3361-9.
30. Karp JE, Gojo I, Greer J, et al. 2006. Tipifarnib (Zarnestra, R115777) as maintenance therapy for adults in complete remission (CR) following induction and consolidation therapies for poor-risk acute myelogenous leukemia (AML): a phase II trial. Blood, 108:780a-781a.
31. Karp JE, Feldman EJ, Morris L, et al. 2006b. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia (AML): phase I trial of oral tipifarnib (T) combined with oral etoposide (E) for adults age 70 who are not candidates for traditional cytotoxic chemotherapy (TCC). Blood, 108:130a.
32. Kho Y, Kim SC, Jiang C, et al. 2004. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc Natl Acad Sci USA, 101:12479-84.
33. Khosravi-Far R, Cox AD, Kato K, et al. 1992. Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ, 3:461-9.
34. Kirschbaum M, Selwyn Stein A, Tuscano J, et al. 2006. A phase I study of the farnesyltransferase inhibitor tipifarnib in a week-on week-off dose schedule in acute myelogenous leukemia. Blood, 108:551a.
35. Klippel A, Escobedo MA, Wachowicz MS, et al. 1998. Activation of phosphatidylinositol-3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol, 18:5699-711.
36. Kurzrock R, Kantarjian HM, Cortes JE, et al. 2003. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase I setting. Blood, 102:4527-34.
37. Kurzrock R, Albitar M, Cortes JE, et al. 2004. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol, 22:1287-92.
38. ®, R115777) in patients with myelodysplastic syndrome: results of a phase I study. Blood, 108:708a.
39. Lancet JE, Willman CL, Bennett JM. 2000. Acute myelogenous leukemia and aging: clinical interactions. Hematol Oncol Clin North Am, 14:251-67.
40. Lancet JE, Karp JE. 2003. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood, 102:3880-9.
41. Lancet JE, Gojo I, Gotlib J, et al. 2007. A phase 2 study of the farnesyltrans-ferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood, 109:1387-94.
42. Lara PN, Law LY Jr, Wright JJ, et al. 2005. Intermittent dosing of the farne-syl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium trial. Anticancer Drugs, 16:317-21.
43. Lebowitz PF, Casey PJ, Prendergast GC, et al. 1997. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem, 272:15591-4.
44. Lebowitz PF, Sakamuro D, Prendergast GC. 1997b. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res, 57:708-13.
45. Leith CP, Kopecky KJ, Godwin J, et al. 1997. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89:3323-9.
46. Liao H, Winkfein RJ, Mack G, et al. 1995. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol, 130:507-18.
47. Liu AX, Rane N, Liu JP, et al. 2001. RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol, 21:6906-12.
48. Löwenberg B, Downing JR, Burnett A. 1999. Acute myeloid leukemia. N Engl J Med, 41:1051-62.
49. Lowy DR, Willumsen BM. 1993. Function and regulation of ras. Annu Rev Biochem, 62:851-91.
50. MacKenzie KL, Dolnikov A, Millington M, et al. 1999. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood, 93:2043-56.
51. Mazure NM, Chen EY, Laderoute KR, et al. 1997. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphati-dylinositol-3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood, 90:3322-31.
52. Morgan MA, Ganser A, Reuter CWM. 2003. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia, 17:1482-98.
53. Nagata H, Hansen WJ, Freeman B, et al. 1998. Mammalian cytosolic DnaJ homologues affect the hsp70 chaperone-substrate reaction cycle, but do not interact directly with nascent or newly synthesized proteins. Biochemistry, 37:6924-38.
54. Punt CJ, van Maanen L, Bol CJ, et al. 2001. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs, 12:193-7.
55. Raponi M, Belly RT, Karp JE, et al. 2004. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer, 4:56-68.
56. Raponi M, Harousseau JL, Lancet JE, et al. 2007. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res, 13:2254-60.
57. Ridley AJ, Hall A. 1992. The small Gtp-binding protein Rho regulates the assembly of focal adhesions and action stress fibers in response to growth factors. Cell, 70:389-99.
58. Rowinsky EK, Windle JJ, Von Hoff DD. 1999. Ras protein farnesyl-transferase: A strategic target for anticancer therapeutic development. J Clin Oncol, 17:3631-52.
59. Rowe JM. 2000. Treatment of acute myelogenous leukemia in older adults. Leukemia, 14:480-7.
60. Sinensky M, Fantle MK, Dalton M. 1994. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res, 54:3229-32.
61. Suzuki N, Urano J, Tamanoi F. 1998. Franesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci USA, 95:15356-61.
62. Venet M, End D, Angibaud P. 1998. Farnesyl protein transferase inhibitor ZARNESTRA R115777 history of a discovery. Curr Top Med Chem, 3:1095-102.
63. Wang J, Kirby CE, Herbst R. 2002. The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem, 277:46659-68.
64. Wheeler AP, Ridley AJ. 2004. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res, 301:43-9.
65. Whyte DB, Kirschmeier P, Hockenberry TN, et al. 1997. Kand N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem, 272:14459-64.
66. Yao X, Anderson KL, Cleveland DW. 1997. The microtubule-dependent motor centromere-associated protein E (CENP-E) is an integral component of kinetochore corona fibers that link centromeres to spindle microtubules. J Cell Biol, 139:435-47.
67. Zhang FL, Kirschmeier P, Carr D, et al. 1997. Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem, 272:10232-9.
68. Zhu K, Gerbino E, Beaupre DM, et al. 2005. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood, 105:4759-66.
69. Zimmerman TM, Harlin H, Odenike OM, et al. 2004. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed or refractory hematologic malignancies. J Clin Oncol, 22:4816-22.
70. Zujewski J, Horak ID, Bol CJ, et al. 2000. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol, 18:927-41.